Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway

S. J. Li, Subbiah Sivam, J. F. McGinty, Y. S. Huang, J. S. Hong

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The influence of the dopaminergic system on the striatonigral tachykinin pathway was studied in male Fischer 344 rats. Activation of dopamine receptors by subacute administration of apomorphine (APO; 5 mg/kg s.c. twice daily for 7 days) significantly increased striatonigral substance P-like immunoreactivity (SP-LI; 73% over control in striatum, 63% over control in substantia nigra) and substance K-like immunoreactivity (49% over control in striatum, 15% over control in substantia nigra). The changes in striatonigral SP-LI were dose dependent (0.5-5 mg/kg), time related (one, three or seven daily injections) and region specific as changes were not observed in frontal cortex, hippocampus and hypothalamus. The increase of SP-LI and substance K-like immunoreactivity was completely prevented by the dopamine receptor blocker, haloperidol, which, by itself, caused a slight decrease of both peptide levels. Immunocytochemical staining revealed enhanced SP-LI in neurons restricted to striatal patches and fibers in substantia nigra pars reticulata after APO treatment as compared with SP-LI intensity in control. In order to understand the molecular mechanism underlying the APO-induced increase in the level of tachykinins, the abundance of messenger RNA coding for preprotachykinin was quantified by blot hybridization. It was found that subacute administration of APO increased the abundance of preprotachykinin messenger RNA in the striatum. These results suggest that stimulation of dopaminergic receptors leads to an acceleration of tachykinin biosynthesis. A single dose of APO (2.5 mg/kg s.c.) induced a slight but significant reduction in striatal SP-LI (82% of control). This result suggests that APO triggers the release of tachykinins. Thus, the increase in the level of these peptides after subacute administration of dopamine agonists may be due to a compensatory increase in biosynthesis. In summary, this study demonstrates that the dopaminergic system exerts potent regulation of the metabolism of tachykinins in the striatonigral pathway. Dopaminergic stimulation leads to an increase, whereas dopaminergic inhibition leads to a decrease, in the biosynthesis of tachykinins.

Original languageEnglish (US)
Pages (from-to)792-798
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume243
Issue number2
StatePublished - 1987
Externally publishedYes

Fingerprint

Tachykinins
Neurokinin A
Corpus Striatum
Dopamine Receptors
Substantia Nigra
Messenger RNA
Peptides
Dopamine Antagonists
Apomorphine
Dopamine Agonists
Inbred F344 Rats
Frontal Lobe
Haloperidol
Substance P
Hypothalamus
Hippocampus
Staining and Labeling
Neurons
Injections

ASJC Scopus subject areas

  • Pharmacology

Cite this

Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway. / Li, S. J.; Sivam, Subbiah; McGinty, J. F.; Huang, Y. S.; Hong, J. S.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 243, No. 2, 1987, p. 792-798.

Research output: Contribution to journalArticle

Li, S. J. ; Sivam, Subbiah ; McGinty, J. F. ; Huang, Y. S. ; Hong, J. S. / Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway. In: Journal of Pharmacology and Experimental Therapeutics. 1987 ; Vol. 243, No. 2. pp. 792-798.
@article{7ff1d2a027aa49d79fd9ba5587df12c4,
title = "Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway",
abstract = "The influence of the dopaminergic system on the striatonigral tachykinin pathway was studied in male Fischer 344 rats. Activation of dopamine receptors by subacute administration of apomorphine (APO; 5 mg/kg s.c. twice daily for 7 days) significantly increased striatonigral substance P-like immunoreactivity (SP-LI; 73{\%} over control in striatum, 63{\%} over control in substantia nigra) and substance K-like immunoreactivity (49{\%} over control in striatum, 15{\%} over control in substantia nigra). The changes in striatonigral SP-LI were dose dependent (0.5-5 mg/kg), time related (one, three or seven daily injections) and region specific as changes were not observed in frontal cortex, hippocampus and hypothalamus. The increase of SP-LI and substance K-like immunoreactivity was completely prevented by the dopamine receptor blocker, haloperidol, which, by itself, caused a slight decrease of both peptide levels. Immunocytochemical staining revealed enhanced SP-LI in neurons restricted to striatal patches and fibers in substantia nigra pars reticulata after APO treatment as compared with SP-LI intensity in control. In order to understand the molecular mechanism underlying the APO-induced increase in the level of tachykinins, the abundance of messenger RNA coding for preprotachykinin was quantified by blot hybridization. It was found that subacute administration of APO increased the abundance of preprotachykinin messenger RNA in the striatum. These results suggest that stimulation of dopaminergic receptors leads to an acceleration of tachykinin biosynthesis. A single dose of APO (2.5 mg/kg s.c.) induced a slight but significant reduction in striatal SP-LI (82{\%} of control). This result suggests that APO triggers the release of tachykinins. Thus, the increase in the level of these peptides after subacute administration of dopamine agonists may be due to a compensatory increase in biosynthesis. In summary, this study demonstrates that the dopaminergic system exerts potent regulation of the metabolism of tachykinins in the striatonigral pathway. Dopaminergic stimulation leads to an increase, whereas dopaminergic inhibition leads to a decrease, in the biosynthesis of tachykinins.",
author = "Li, {S. J.} and Subbiah Sivam and McGinty, {J. F.} and Huang, {Y. S.} and Hong, {J. S.}",
year = "1987",
language = "English (US)",
volume = "243",
pages = "792--798",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway

AU - Li, S. J.

AU - Sivam, Subbiah

AU - McGinty, J. F.

AU - Huang, Y. S.

AU - Hong, J. S.

PY - 1987

Y1 - 1987

N2 - The influence of the dopaminergic system on the striatonigral tachykinin pathway was studied in male Fischer 344 rats. Activation of dopamine receptors by subacute administration of apomorphine (APO; 5 mg/kg s.c. twice daily for 7 days) significantly increased striatonigral substance P-like immunoreactivity (SP-LI; 73% over control in striatum, 63% over control in substantia nigra) and substance K-like immunoreactivity (49% over control in striatum, 15% over control in substantia nigra). The changes in striatonigral SP-LI were dose dependent (0.5-5 mg/kg), time related (one, three or seven daily injections) and region specific as changes were not observed in frontal cortex, hippocampus and hypothalamus. The increase of SP-LI and substance K-like immunoreactivity was completely prevented by the dopamine receptor blocker, haloperidol, which, by itself, caused a slight decrease of both peptide levels. Immunocytochemical staining revealed enhanced SP-LI in neurons restricted to striatal patches and fibers in substantia nigra pars reticulata after APO treatment as compared with SP-LI intensity in control. In order to understand the molecular mechanism underlying the APO-induced increase in the level of tachykinins, the abundance of messenger RNA coding for preprotachykinin was quantified by blot hybridization. It was found that subacute administration of APO increased the abundance of preprotachykinin messenger RNA in the striatum. These results suggest that stimulation of dopaminergic receptors leads to an acceleration of tachykinin biosynthesis. A single dose of APO (2.5 mg/kg s.c.) induced a slight but significant reduction in striatal SP-LI (82% of control). This result suggests that APO triggers the release of tachykinins. Thus, the increase in the level of these peptides after subacute administration of dopamine agonists may be due to a compensatory increase in biosynthesis. In summary, this study demonstrates that the dopaminergic system exerts potent regulation of the metabolism of tachykinins in the striatonigral pathway. Dopaminergic stimulation leads to an increase, whereas dopaminergic inhibition leads to a decrease, in the biosynthesis of tachykinins.

AB - The influence of the dopaminergic system on the striatonigral tachykinin pathway was studied in male Fischer 344 rats. Activation of dopamine receptors by subacute administration of apomorphine (APO; 5 mg/kg s.c. twice daily for 7 days) significantly increased striatonigral substance P-like immunoreactivity (SP-LI; 73% over control in striatum, 63% over control in substantia nigra) and substance K-like immunoreactivity (49% over control in striatum, 15% over control in substantia nigra). The changes in striatonigral SP-LI were dose dependent (0.5-5 mg/kg), time related (one, three or seven daily injections) and region specific as changes were not observed in frontal cortex, hippocampus and hypothalamus. The increase of SP-LI and substance K-like immunoreactivity was completely prevented by the dopamine receptor blocker, haloperidol, which, by itself, caused a slight decrease of both peptide levels. Immunocytochemical staining revealed enhanced SP-LI in neurons restricted to striatal patches and fibers in substantia nigra pars reticulata after APO treatment as compared with SP-LI intensity in control. In order to understand the molecular mechanism underlying the APO-induced increase in the level of tachykinins, the abundance of messenger RNA coding for preprotachykinin was quantified by blot hybridization. It was found that subacute administration of APO increased the abundance of preprotachykinin messenger RNA in the striatum. These results suggest that stimulation of dopaminergic receptors leads to an acceleration of tachykinin biosynthesis. A single dose of APO (2.5 mg/kg s.c.) induced a slight but significant reduction in striatal SP-LI (82% of control). This result suggests that APO triggers the release of tachykinins. Thus, the increase in the level of these peptides after subacute administration of dopamine agonists may be due to a compensatory increase in biosynthesis. In summary, this study demonstrates that the dopaminergic system exerts potent regulation of the metabolism of tachykinins in the striatonigral pathway. Dopaminergic stimulation leads to an increase, whereas dopaminergic inhibition leads to a decrease, in the biosynthesis of tachykinins.

UR - http://www.scopus.com/inward/record.url?scp=0023481954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023481954&partnerID=8YFLogxK

M3 - Article

VL - 243

SP - 792

EP - 798

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -